Q-omics provides the consensus-scored GAPDHP70 profile across patient tissues and cancer cell-line models. GAPDHP70 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, GAPDHP70 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, GAPDHP70 RNA expression shows 13,160 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LIHC, KIRC, and KIRP as cancer lineages where GAPDHP70 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP70 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP70 survival associations across molecular data types. GAPDHP70 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP70 RNA expression–survival associations across cancer types. High GAPDHP70 expression shows unfavorable associations in LIHC, LGG and LUAD, but favorable associations in LUSC, OV and KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for GAPDHP70 RNA expression.
This table summarizes GAPDHP70 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP70. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP70 shows higher tumor expression in KIRC, COAD, HNSC, UCEC, LUSC and KIRP. The KIRC box plot shows higher GAPDHP70 RNA expression in tumor versus normal tissue (log2 FC = +0.557, t-test p < 0.001).
This table shows molecular features associated with GAPDHP70 in patient tissues and cancer cell lines. In patient samples, GAPDHP70 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
